Maravai LifeSciences Holdings Inc. Class A Common Stock vs Under Armour Inc Class A — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Under Armour Inc Class A trades at $4.79 (market cap $2.08B). The key difference: Under Armour Inc Class A is far larger — about 2.1× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Under Armour Inc Class A for 99 Days on average.
| MRVI | UAA | |
|---|---|---|
Market Cap | $972.90M | $2.08B |
Volume | 4,325,710 | 7,012,020 |
Sector | Health | Consumer Cyclical |
52-Week High | $9.00 | $8.14 |
52-Week Low | $2.83 | $4.17 |
Typical Hold Time | 0 Days | 99 Days |
Enterprise Value | $1.08B | $3.06B |
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Under Armour (UAA) trades at $4.79, down 2.84% on the day, amid mixed signals. The stock shows a bullish technical trend but faces fundamental headwinds with a net loss of $201.27M in 2025 and negative profit margins. Recent news highlights the company's focus on product simplification and margin recovery despite revenue weakness, with Q1 2027 earnings beating estimates but revenue falling short.
The outlook is cautious; while cost discipline supports margins, persistent revenue declines and negative cash flow pose risks. Analyst consensus is a 'Hold' with a $5.79 price target, suggesting limited upside. Investors should weigh margin improvements against top-line challenges and high short interest, which could lead to volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →